The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending Talzenna (talazoparib) for HER2- negative, locally 19 January 2024
US healthcare lobbyist Vital Transformation has released a document outlining objections to the expansion drug pricing policies under the Inflation Reduction Ac 19 January 2024
The US Food and Drug Administration has authorized a drug importation program in Florida, as the state seeks to benefit from lower cost medicines across the bor 8 January 2024
Californian rare disease company Ultragenyx Pharmaceutical (Nasdaq: RARE) has received a positive reimbursement decision from the UK’s health technology assesso 5 January 2024
Lynparza (olaparib) has been recommended for use alongside abiraterone and prednisone or prednisolone for untreated hormone-relapsed metastatic prostate cancer 21 December 2023
Lif, the industry organization for Danish and foreign pharmaceutical companies in Denmark, has held a debate to discuss access to new medicines. 18 December 2023
US pharma trade group the Pharmaceutical Research and Manufacturers of America (PhRMA) has presented research suggesting the Inflation Reduction Act (IRA) could 18 December 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.